Three clinical strains of Escherichia coli (p168, p517 and p667) were collected in 2006 from three hospitals in Anhui Province (China). PCR and DNA sequencing revealed that E. coli p168 carried a novel extended-spectrum b-lactamase (ESBL), which was designated CTX-M-87. The extended-spectrum b-lactamase which was carried by E. coli p517 and E. coli p667 was previously named CTX-M-65. The deduced amino acid sequence of CTX-M-87, with pI 9.1, differed from that of CTX-M-14 by the substitutions Ala77AVal and Pro167ALeu. Like CTX-M-14, CTX-M-87 had a more potent hydrolytic activity against cefotaxime than against ceftazidime and had high affinity for cefuroxime and cefotaxime. These data show that mutations at position 167 in CTX-M do not always affect catalytic activity and substrate preference.
INTRODUCTION
The first plasmid-borne extended-spectrum b-lactamase (ESBL) of the CTX-M type (MEN-1, CTX-M-1) was reported in 1990 (Bauernfeind et al., 1990; Bush, 2001) . In contrast to many ESBLs found previously, the early CTX-M enzymes determined high-level resistance to cefotaxime but did not significantly affect ceftazidime (Barthélémy et al., 1992) . CTX-M enzymes have caused outbreaks of cefotaxime-resistant enterobacteria mainly in South America, Eastern Europe and Japan (Bradford et al., 1998; Gniadkowski et al., 1998; Ishii et al., 1995; Ma et al., 1998) . From the early 1990s to the present, members of the Enterobacteriaceae (mostly Escherichia coli) producing different ESBLs, such as the CTX-M enzymes, have emerged within the hospital and community setting as an important cause of urinary tract infections (Babic et al., 2006) . Like Eastern Europe and Japan (Gazouli & Legakis, 1998; Gniadkowski et al., 1998; Bonnet, 2004; Gazouli et al., 1998a) , China is an important source of CTX-M-producing bacteria. Our studies that have investigated community-onset infections caused by CTX-M-producing E. coli isolates showed that these isolates are often not clonally related (Cheng et al., 2008) .
The CTX-M-type enzymes are much more active against cefotaxime than against ceftazidime and aztreonam. The amino acid residues proposed to be critical for their extended-spectrum activity, Ser237 and Arg276, seem to be involved in the cefotaxime-hydrolysing activity, but mutagenesis experiment of these residues led to only slight changes in their catalytic activities (Gazouli et al., 1998a, b) . Pro167 is located in the omega loop. Substitutions at position 167 were observed in more than 10 CTX-M mutants which exhibited an improved enzymic activity against ceftazidime (Delmas et al., 2006) . In the current study, we report a novel CTX-M-type cefotaxime-hydrolysing b-lactamase, which we have designated CTX-M-87. The other enzyme which we studied was CTX-M-65. The deduced amino acid sequence of CTX-M-87 differed from that of CTX-M-14 by the substitutions Ala77AVal and Pro167ALeu; CTX-M-65 differed from CTX-M-14 by the substitutions Ala77AVal and Ser272AArg. Conjugation experiment. To determine whether resistance was transferable, conjugations were performed with a streptomycinresistant recipient, E. coli C 600 (Lac 2 ). Conjugation mixtures were plated on MacConkey agar (Tianhe) containing streptomycin (500 mg ml
21
) and cefotaxime (2 mg ml
) and then incubated for approximately 20 h at 37 uC.
Antimicrobial susceptibility testing. MICs were determined with the Mueller-Hinton agar (Oxoid) dilution method. Throughout this study, the results were interpreted by using the Clinical and Laboratory Standards Institute guidelines (CLSI, 2007) . The final inoculating concentration of bacteria was 5610 5 c.f.u. ml
. ESBL phenotype was detected by using the double-disc synergy method (CLSI, 2007) .
Preparation of crude extracts of b-lactamase and IEF. Crude cell homogenates for the detection of b-lactamases were prepared from fresh overnight culture by sonication. b-Lactamase activity was revealed by staining the gel with 0.5 mg of the chromogenic b-lactam nitrocefin (Oxoid) ml
. IEF was performed with a PhastSystem apparatus (Amersham Pharmacia Biotech) as described previously (Weill et al., 2004) .
PCR amplification of b-lactamase genes and sequence analysis. The full-length amplification products of bla CTX-M-9T (F: 59-TTGAATTCGCGCATGGTGACAAAGAGAGTGCAA-39; R: 59-TTGGATCCGTTACAGCCCTTCGGCGATGATTC-39) were amplified using 30 cycles of denaturation for 40 s at 94 uC, annealing for 40 s at 57 uC, and extension for 1 min at 70 uC. All nucleotide sequences were determined by bidirectional sequencing with the 3730 automatic DNA sequencer (Sangon).
Cloning of the CTX-M gene. Open reading frames encoding CTX-M-type enzymes were amplified by PCR with primers CTX-M-9T-F and CTX-M-9T-R, which included restriction sites for the enzymes EcoRI (TaKaRa) and BamHI (TaKaRa). The PCR product was purified using purification kits (Axygen). The PCR products were digested with these two enzymes and ligated into the corresponding restriction sites of modified plasmid pHSG 398 (Cheng et al., 2008) . The resulting plasmids, pHSG 398 -CTX-M-87 and pHSG 398 -CTX-M-65, which encoded CTX-M-87 and CTX-M-65, respectively, were transformed into E. coli JM109. The transformant was selected on Mueller-Hinton agar supplemented with cefotaxime (2 mg ml
) and chloramphenicol (50 mg ml
). All nucleotide sequences were determined by bidirectional sequencing with the 3730 automatic DNA sequencer.
Determination of steady-state kinetic parameters. The blactamase from each recombinant strain was purified by fast protein liquid chromatography as described previously (Ma et al., 1998) . Seven different substrate concentrations were used to determine the kinetic parameters for each substrate. Each reported parameter is a mean of three independent measurements. PFGE. PFGE of chromosomal DNA for strain typing was carried out as described by Gautom (1997) . Chromosomal DNA was digested with 10 U XbaI (TaKaRa) at 37 uC for 4 h. The DNA fragments were separated by electrophoresis in a 1.2 % (w/v) agarose gel (Agarose NA; Amersham Pharmacia Biotech) with a CHEF Mapper XA System (Bio-Rad) at 175 V and 12 uC for 20 h. The pulse time was increased from 5 to 35s.
RESULTS

Susceptibility testing, conjugation and IEF of b-lactamases
The clinical isolates E. coli p168, E. coli p517 and E. coli p667 were not clonally related (six or more bands at different sizes according to PFGE; data not shown). All three exhibited resistance to broad-spectrum cephalosporins including cefotaxime. The transferability of cefotaxime resistance from the three E. coli strains was assessed using conjugation experiments with an E. coli recipient; transconjugants were selected at similar frequencies (10
24
) from each donor. The MICs of piperacillin, cefotaxime and ceftriaxone against the clinical isolate and the corresponding transconjugant were ¢256 mg ml
21
, ¢64 mg ml 21 and ¢64 mg ml
, respectively. The MICs of various antimicrobial agents for clinical isolates and transconjugants are listed in Table 1 . All clinical isolates produced two or three bands on IEF gel. All transconjugants produced one band. Transconjugants where p168 was the donor produced a b-lactamase with a pI value of 9.1; transconjugants where p517 or p667 were the donors both produced a blactamase with a pI value of 9.3. All clinical strains produced a second b-lactamase with a pI value of 5.4, which was shown to be TEM-1.
Cloning of the b-lactamase genes and DNA sequencing Given the likelihood of the reason for cephalosporin resistance being production of a CTX-M-type b-lactamase, PCR with primers CTX-M-9T-F and CTX-M-9T-R was performed. This was positive for all three clinical isolates, and the PCR products were ligated into plasmid pHSG 398 . The obtained recombinant plasmids were designated pSp168, pSp517 and pSp667 depending upon the template DNA used. They contained an approximately 0.9 kb insert encoding a novel CTX-M enzyme designated CTX-M-87 (from E. coli 168); the other is CTX-M-65 (from E. coli 517 and E. coli 667) which was previously reported, but not characterized (Doi et al., 2008) . The deduced amino acid sequence of CTX-M-87 differed from that of CTX-M-14 by the substitutions Ala (GCC)77AVal (GTC) and Pro (CCT)167ALeu (CTT); CTX-M-65 differed from CTX-M-14 by the substitutions Ala (GCC)77AVal (GTC) and Ser (AGC)272AArg (CGC). When the signal peptide of 28 amino acids is removed (Ambler et al., 1991) , the putative mature enzymes CTX-M-87 and CTX-M-65 consist of 263 amino acid residues with calculated molecular masses of 28 018 Da and 28 071 Da, respectively. MICs conferred by the cloned bla CTX-M genes are shown in Table 1 .
Kinetic parameters of CTX-M-87 and CTX-M-65
We measured kinetic parameters of both purified enzymes against selected b-lactams. The purity of enzyme was .95 %. The K cat and K m values were determined for a representative set of b-lactam antimicrobial agents ( ). The results were coincident with the MICs.
DISCUSSION
The molecular epidemiology of CTX-M-producing E. coli strains on a countrywide scale has been previously described in the UK (Woodford et al., 2004) , Spain (Oteo et al., 2006) , Italy (Mugnaioli et al., 2006) and Canada (Mulvey et al., 2004) . There are over 70 different types of CTX-M b-lactamases, which can be divided into five groups based on their amino acid identities (Bonnet, 2004) : the CTX-M-1 group, the CTX-M-2 group, the CTX-M-8 group, the CTX-M-9 group and the CTX-M-25 group. In China, CTX-M-1 and CTX-M-9 are most common. In China, extended-spectrum b-lactams such as Table 2 . Kinetic parameters (k cat and K m ) and catalytic efficiency (k cat /K m ) of enzymes CTX-M-87, CTX-M-65 and CTX-M-14 against various b-lactams (Cheng et al., 2008) .
The aim of the present study was to characterize a novel CTX-M enzyme designated CTX-M-87; the other enzyme that we characterized was CTX-M-65 b-lactamase. By studying wild-type clinical isolates, transconjugants and transformants, together with purified enzymes, we have shown that CTX-M-87 has very similar properties to those of CTX-M-14.
Amino acid residues Asn104, Asn132, Phe160, Pro167, Gly232, Ser237 and Arg276 play an important role in catalysis by CTX-M b-lactamases (Bonnet et al., 2001; Ma et al., 2002) . Residue 167 located in the omega loop plays an important role in influencing substrate specificity. The cefotaxime-bound crystal structure of Toho-1 indicates that Pro167 of CTX-M type b-lactamases has good contact with the AT moiety. Thus the substitution of Pro167 appears to play an important role in substrate binding, and substitutions at this position are known to lead to the change of resistance pattern conferred by the enzyme, particularly causing an increase in ceftazidime hydrolysis. Poirel et al. (2001) showed that the change of the single amino acid Pro to Ser at position 167 in CTX-M-19 enlarges the catalytic site of the enzyme for ceftazidime; therefore CTX-M-19 confers ceftazidime resistance. Stepanova et al. (2008) reported a Pro167Thr variant of CTX-M-3 conferring higher-level resistance to ceftazidime. However, the results of Kimura et al. (2004) from modelling studies suggest that CTX-M-18 (Pro167) has a larger cavity than CTX-M-19 (Ser167) for binding the AT moiety. As a result of this small but significant difference in the binding cavity within these two enzymes, the recognition mode of the enzymes against blactams may differ for different b-lactams. Thus the mutation at the omega loop site may cause a change (Kimura et al., 2004) . The Pro167Gln substitution indicates the further evolutionary potential of CTX-M enzymes. The observed changes increased the ability to confer resistance against ceftazidime, but tended to reduce resistance to cefepime (Karisik et al., 2006) . CTX-M-45 (Pro167Gln) has an expanded activity towards ceftazidime (Bae et al., 2006) . In 2007, Kimura et al. (2007) reported that the k cat /K m values for Pro167Ser mutants and their respective wild-type enzymes were identical for cefalothin, penicillin and nitrocefin. For cefotaxime, the catalytic efficiency (k cat /K m ) for wild-type enzymes was 3.13-7.12 times higher than that of their respective Pro167Ser mutants. Pro167Ser mutants had k cat /K m values 1.73-2.21 times higher than those of their respective wild-type enzymes. These results indicate that the CTX-M-type b-lactamase family can hydrolyse ceftazidime more efficiently because of the point mutation at position 167. However, in our study, CTX-M-87 was shown to differ from CTX-M-14 by two amino acids, at positions 77 (AlaAVal) and 167 (ProALeu), but there was no obvious effect of this mutation relative to CTX-M-14 (Tables 1 and  2 ). Accordingly, we can conclude that not all mutations at position 167 result in alterations in the kinetic parameters or substrate specificity of CTX-M type b-lactamases.
